SUMMARY
Introduction/Objective As of recently, an increasing number of premenopausal women is being diagnosed with endometrial carcinomas. The objective of our study was to determine if routinely collected clinical and imaging parameters, implying on tumor characteristics, are different in pre- and postmenopausal endometrial carcinoma patients, enabling their appropriate preoperative evaluation.

Methods The study included all patients (n = 209) operated on due to endometrial carcinoma over a period of three years. The diagnosis was based on histopathological findings of exploratory curettage. Medical history was taken for all the patients and they were divided regarding menopausal status. On preoperative ultrasound scan, the endometrial echo pattern was established. The existence of myomas, adnexal masses, free fluid in the abdomen or uterine cavity was noted. Magnetic resonance imaging detected the presence of pelvic metastases and tumor spreading into the uterine cavity, myometrium, cervix, and lymph nodes. Postoperatively, histopathological findings, the tumor stage and grade were established.

Results The majority of women were postmenopausal and secundiparous. Significantly more patients were obese, especially the postmenopausal ones (p = 0.001). Most tumors were endometrioid adenocarcinomas regardless of menopausal status. Irregular/abnormal bleeding (p = 0.037), presence of ascites (p = 0.010), obesity (p = 0.046), and lower parity (p = 0.016) correlated with postmenopausal status. Large exophytic endometrial carcinomas were predominant in younger patients (p = 0.026). Endometrial carcinomas were significantly more often diagnosed in the II FIGO stage in premenopausal patients. There were no other significant differences (endometrial thickness, uterine homogeneity, echogenicity, tumor infiltration and spreading, histopathological type and grade) between pre- and postmenopausal endometrial carcinoma patients.

Conclusions Few differences between pre- and postmenopausal endometrial carcinoma patients existed and the most prominent ones were obesity, parity, irregular/abnormal bleeding, and tumor growth into the cavity.

Keywords: endometrial carcinoma; menopausal status; BMI; irregular abnormal bleeding; preoperative evaluation; ultrasound scan and MRI

INTRODUCTION
Endometrial carcinoma is one of the most common malignant tumors of the female genital system. It accounts for about 4% of all malignancies in women worldwide [1]. Typical symptoms are irregular/abnormal bleeding and pelvic pain [2]. So far established risk factors, such as obesity, impaired lipid and carbohydrate metabolism, infertility and low parity, late onset of menopause and anovulatory cycles, are related to hyperestrogenism [3, 4].

Occurrence of endometrial carcinoma increases with age and it usually arises in postmenopausal women. However, as of recently, an increasing number of younger premenopausal women have been diagnosed with endometrial carcinoma, possibly due to an epidemic of obesity and physical inactivity even of young girls [1, 5].

The differential diagnosis of different pathological conditions on the base of secretory endometrium can be difficult [5]. Good preoperative discrimination between benign and malignant endometrial proliferations is essential for appropriate therapeutic approach. In postmenopausal women, vaginal bleeding and/or endometrial thickness measured by transvaginal ultrasonography above 5 mm are considered to be very suspicious of endometrial carcinoma and present an indication for exploratory curettage [6]. However, currently
there are no algorithms based on clinical, laboratory, and imaging parameters for the assessment of premenopausal women that may have endometrial carcinoma.

Moreover, ultrasonographic examination sometimes has low diagnostic reliability with numerous false positive findings [7]. Although the exact diagnosis is achieved by examination of endometrial tissue samples obtained on fractionated exploratory curettage or hysterectomy with endometrial biopsy, detection of malignant invasion of the myometrium is usually diagnosed by histopathological analysis only after hysterectomy [8].

The objective of the study was to determine if routinely collected clinical and imaging parameters, implying on tumor characteristics [histopathological findings (HP), grade, stage], are different in pre- and postmenopausal women, enabling appropriate preoperative evaluation of different age group patients with endometrial carcinoma.

METHODS

The study included all patients who were operated at the Clinic of Obstetrics and Gynecology, Clinical Center of Serbia, over a three-year period (January 1, 2011 to December 31, 2013) due to endometrial carcinoma. The initial diagnosis and the decision for operative treatment were based on HP of exploratory curettage that all patients had either due to irregular/abnormal bleeding or endometrial thickening registered by ultrasound on a regular gynecological check-up. Upon admission for operation, the standard medical history [irregular/abnormal bleeding, age, parity, menopausal status and the age of menopause, the use of hormone replacement therapy or tamoxifen, comorbidities like breast carcinoma, hypertension, diabetes mellitus, etc.] was taken for all patients and their body mass index (BMI) was calculated. Preoperatively, all the patients had a detailed trans-vaginal ultrasound (TVUS) scan with the measurement of endometrial thickness. The homogeneity and echogenicity of the uterine tissue were evaluated. The existence of myomas and adnexal masses were noted. The presence of free fluid in the abdomen (ascites) as well as in the uterine cavity was also registered. Furthermore, the patients underwent the magnetic resonance imaging (MRI) of the pelvis. By analyzing the MRI images, we determined tumor spreading into the uterine cavity, the myometrium, the cervix, and the lymph nodes, as well as the presence of pelvic metastases. Post-operatively, HP of the tumor (type, grade, and stage) were analyzed. Staging was performed according to the new International Federation of Gynecologist and Obstetricians (FIGO) classification. All the women were divided regarding their menopausal status and the obtained data was analyzed accordingly.

Upon admission to hospital, all the women gave informed consent to all the diagnostic and therapeutic procedures required for this study, as well as to their enrolment in the study sample. Study procedure was performed in accordance with the ethical standards and it was approved by the Clinic Ethics Committee.

For the statistical analysis, we used methods of descriptive and analytical statistics (percentages, χ² test, Kruskal–Wallis nonparametric ANOVA, Spearman correlation, binary linear regression) and IBM SPSS Statistics, Version 20.0 (IBM Corp., Armonk, NY, USA).

RESULTS

The study involved 209 women who were operated on due to endometrial carcinoma at the Clinic for Obstetrics and Gynecology, Clinical Center of Serbia, throughout a period of three years (2011–2013).

In the examined population we registered significantly more postmenopausal (168; 80.4%) than premenopausal (41; 19.6%) women with endometrial carcinomas ($\chi^2 = 77.172; p = 0.001$). The majority of patients ($n = 83; 39.71\%$) were in their 60s, with an average age of 63.41 ± 9.92 years ($\text{min.} = 36; \text{max.} = 85$). The mean BMI of investigated patients was $28.70 \pm 5.42$ (min. = 17; max. = 40.9; premenopausal BMI $28.97 \pm 6.66$; postmenopausal BMI $28.63 \pm 5.1$). Significantly more women were obese (BMI > 25 kg/m²), especially in the postmenopausal group. The majority of women of both groups had two births and no abortions (Table 1).

Significantly more patients neither had previously diagnosed breast carcinoma nor administered therapy for it. Only nine women had ever used hormonal replacement therapy. Investigated patients mostly did not have other comorbidities, but hypertension was very frequent. The majority of patients had irregular/abnormal bleeding. This was especially prominent for postmenopausal women (Table 1).

The mean endometrial thickness on preoperative TVUS scan was $12.21 \pm 8.46$ mm (min. = 3 mm; max. = 39 mm; premenopausal $13.45 \pm 10.8$; postmenopausal $11.91 \pm 7.79$). Significantly more women had pathologically increased endometrial thickness regardless of their menopausal status (Table 2). Most tumors had exophytic growth filling the uterine cavity. On TVUS scan, significantly more both pre- and postmenopausal women had homogenous but hyper-echogenic endometrial presentation (Table 2). Significantly more women, regardless of their menopausal status, neither had TVUS findings of fluid in the uterus or abdomen, nor pelvic metastases, myomas or adnexal tumors on MRI. Myometrium was usually infiltrated less than one-third of its thickness in both investigated groups (Table 2).

Four different histopathological diagnoses of endometrial carcinomas were registered. The majority of tumors were endometrioid adenocarcinomas regardless of menopausal status. Nevertheless, there were no cases of carcinosarcoma and clear cell carcinomas in the premenopausal group. The majority of carcinomas in postmenopausal women were in FIGO stage I with grade G1, NG1, while in the premenopausal group endometrial carcinomas were mostly registered in stage II and their predominant grade was G2, NG2 (Table 3).

Having irregular/abnormal bleeding, obesity and lower parity were significantly positively correlated with postmenopausal status. Ascites registered by MRI was
Table 1. Frequency of assessed characteristics in pre- and postmenopausal women and the significance of differences between tested parameter categories in the group

| Parameter                  | Category          | Premenopausal women | Postmenopausal women | Total population |
|----------------------------|-------------------|----------------------|-----------------------|------------------|
|                            | Number | %     | Number | %     | Number | %     |
| Body mass index            |         |       |        |       |        |       |
| appropriate                | 15      | 36.6  | 37     | 22    | 52     | 24.9  |
| obesity                    | 26      | 63.4  | 131    | 78    | 157    | 75.1  |
| p                          | 0.086   | 0.001 | 0.001  |        |        |       |
| Irregular/abnormal bleeding| no      | 14     | 34.1   | 32    | 19     | 46    | 22    |
|                           | yes     | 27     | 65.9   | 136   | 81     | 163   | 78    |
| p                          | 0.042   | 0.001 | 0.001  |        |        |       |
| Parity                     | 0       | 6      | 14.6   | 29    | 17.3   | 35    | 16.8  |
|                           | 1       | 15     | 36.6   | 40    | 23.8   | 55    | 26.3  |
|                           | 2       | 13     | 31.7   | 87    | 51.8   | 100   | 47.8  |
|                           | 3 and more| 7     | 17.1   | 12    | 7.1    | 19    | 9.1   |
| p                          | 0.125   | 0.001 | 0.001  |        |        |       |
| Breast carcinoma           | no      | 38     | 92.7   | 157   | 93.5   | 195   | 93.3  |
|                           | yes     | 3      | 7.3    | 11    | 6.5    | 14    | 6.7   |
| p                          | 0.001   | 0.001 | 0.001  |        |        |       |
| Tamoxifen use              | no      | 40     | 97.6   | 157   | 93.5   | 197   | 94.3  |
|                           | yes     | 1      | 2.4    | 11    | 6.5    | 12    | 5.7   |
| p                          | 0.001   | 0.001 | 0.001  |        |        |       |
| Hormonal substitution      | no      | 36     | 87.8   | 164   | 97.6   | 200   | 95.7  |
|                           | yes     | 5      | 12.2   | 4     | 2.4    | 9     | 4.3   |
| p                          | 0.001   | 0.001 | 0.001  |        |        |       |
| Comorbidities              | no      | 25     | 61     | 59    | 35.1   | 84    | 40.2  |
|                           | HT      | 8      | 19.5   | 73    | 43.5   | 81    | 38.8  |
| diabetes mellitus         | 1       | 2.4    | 6      | 3.6   | 7      | 3.3   |
| both HT / DM or other     | 7       | 17.1   | 30     | 17.9  | 37     | 17.7  |
| p                          | 0.001   | 0.001 | 0.001  |        |        |       |

p – difference between categories of tested parameter in the group; HT – hypertension; DM – diabetes mellitus

Table 2. Examined parameters of tumors in pre- and postmenopausal women and the significance of differences between tested parameter categories in the group

| Parameter                  | Category          | Premenopausal women | Postmenopausal women | Total population |
|----------------------------|-------------------|----------------------|-----------------------|------------------|
|                            | Number | %     | Number | %     | Number | %     |
| Homogeneity on TVUS        | no      | 13     | 31.7   | 75     | 44.6   | 88    | 42.1  |
|                           | yes     | 28     | 68.3   | 93     | 55.4   | 121   | 57.9  |
| p                          | 0.019   | 0.165 | 0.001  |        |        |       |
| Echogenicity on TVUS       | normal  | 16     | 39     | 74     | 44     | 90    | 43.1  |
|                           | hyper   | 25     | 61     | 94     | 56     | 119   | 56.9  |
| p                          | 0.160   | 0.123 | 0.001  |        |        |       |
| Endometrium on TVUS        | ≤ 5 mm  | 9      | 22     | 36     | 21.4   | 45    | 21.5  |
|                           | > 5 mm  | 32     | 78     | 132    | 78.6   | 164   | 78.5  |
| p                          | 0.001   | 0.001 | 0.001  |        |        |       |
| IU fluid on TVUS           | no      | 29     | 70.7   | 137    | 81.5   | 166   | 79.4  |
|                           | yes     | 12     | 29.3   | 31     | 18.5   | 43    | 20.6  |
| p                          | 0.008   | 0.001 | 0.001  |        |        |       |
| Myoma on TVUS              | no      | 31     | 75.6   | 129    | 76.8   | 160   | 76.6  |
|                           | yes     | 10     | 24.4   | 39     | 23.2   | 49    | 23.4  |
| p                          | 0.001   | 0.001 | 0.001  |        |        |       |
| Adnexal tumor on TVUS      | no      | 36     | 87.8   | 150    | 89.3   | 186   | 89    |
|                           | yes     | 5      | 12.2   | 18     | 10.7   | 23    | 11    |
| p                          | 0.001   | 0.001 | 0.001  |        |        |       |
| Ascites on TVUS            | no      | 33     | 80.5   | 157    | 93.5   | 190   | 90.9  |
|                           | yes     | 8      | 19.5   | 11     | 6.5    | 19    | 9.1   |
| p                          | 0.001   | 0.001 | 0.001  |        |        |       |
| Uterine cavity MRI         | without tumor| 10   | 24.4   | 73     | 43.5   | 83    | 39.7  |
| filled with tumor          | 31     | 75.6   | 95     | 56.5   | 126   | 60.3  |
| p                          | 0.001   | 0.001 | 0.001  |        |        |       |
significantly more frequent in postmenopausal women, while exophytic growth of endometrial carcinoma that filled out the uterine cavity was usually seen in younger patients. Moreover, FIGO stage was more advanced in premenopausal women. There were no other significant correlations or differences in examined parameters between pre- and postmenopausal endometrial carcinoma patients (Table 4).

A significant equation was constructed that shows which clinical, TVUS, and MRI parameters assessed together can be used for differentiation between pre- and postmenopausal endometrial carcinoma patients (Table 4).

### Table 3. Postoperative diagnoses of tumors in pre- and postmenopausal women and the significance of differences between tested parameter categories in the group

| Parameter                      | Category            | Premenopausal women | Postmenopausal women | Total population |
|--------------------------------|---------------------|----------------------|-----------------------|------------------|
|                                | Number | %       | Number | %       | Number | %       |
| **Cervix on MRI**              |         |         |        |         |        |         |
| benign                         | 28      | 68.3    | 115    | 68.5    | 143    | 68.4    |
| malignant cells                | 13      | 31.7    | 53     | 31.5    | 66     | 31.6    |
| p                              | 0.019   |         | 0.001  |         | 0.001  |         |
| **Lymph nodes on MRI**         |         |         |        |         |        |         |
| benign                         | 35      | 85.4    | 150    | 89.3    | 185    | 88.5    |
| malignant cells                | 6       | 14.6    | 18     | 10.7    | 24     | 11.5    |
| p                              | 0.001   |         | 0.001  |         | 0.001  |         |
| **MRI pelvic metastases**      |         |         |        |         |        |         |
| no                             | 35      | 85.4    | 155    | 92.3    | 190    | 90.9    |
| yes                            | 6       | 14.6    | 13     | 7.7     | 19     | 9.1     |
| p                              | 0.001   |         | 0.001  |         | 0.001  |         |
| **Myometrium infiltration on MRI** |        |         |        |         |        |         |
| unaffected                     | 4       | 9.8     | 13     | 7.7     | 17     | 8.1     |
| < 1/3                          | 23      | 56.1    | 105    | 62.5    | 128    | 61.2    |
| 1/3–2/3                        | 13      | 31.7    | 45     | 26.8    | 58     | 27.8    |
| whole                          | 1       | 2.4     | 5      | 3       | 6      | 2.9     |
| p                              | 0.001   |         | 0.001  |         | 0.001  |         |

TVUS – transvaginal ultrasound; MRI – magnetic resonance imaging; IU – intrauterine

**DISCUSSION**

Endometrial carcinoma is usually registered in women older than 60 years [9]. This finding is consistent with our study, in which the average age of patients was 63 years. Still, the youngest patient was only 36 years old.

In some reports, older age, tumor grade, involvement of the lower uterine segment and lymphovascular infiltration were proven as significant predictive factors of endometrial malignancy, influencing also the patient’s survival [9].
Studies also confirmed that myometrial invasion, tumor diameter, cervical stromal invasion, and lymphovascular space invasion were the most important parameters for preoperative evaluation and therapy type determination in patients with endometrial malignancies [10].

According to the literature data, only a few studies have evaluated the influence of risk factors for endometrial carcinoma in women of different ages (younger – premenopausal, and older – postmenopausal). Early menarche and nulliparity were correlated with increased endometrial carcinoma risk in premenopausal, but not in postmenopausal women in some investigations. Late menopause showed a stronger association with endometrial carcinoma in older (over 65 years) than in premenopausal patients [11, 12]. Parity in the population we tested was found to be a significant predictive factor for malignancy only in postmenopausal women.

Women with elevated endogenous estrogen levels have an increased risk of endometrial carcinoma. The diagnosis of polycystic ovarian syndrome has been made in up to 30% of cases with endometrial carcinoma in selected groups of premenopausal women [12]. Obesity was confirmed through numerous studies as the main risk factor for endometrial carcinoma [11, 12]. Some authors suggest that this association is consistent only for postmenopausal women, while others confirmed correlation in premenopausal women as well [12]. In obesity, there is an increased level of free estrogen due to increased conversion of fatty tissues from androstenedione. Estrogen leads to chronic proliferation of endometrial cells, increasing the risk of carcinoma occurrence [13, 14]. In our population, 75% of the patients were obese (BMI > 25), indicating that being overweight raises the risk of endometrial malignancy. Still, the obesity was proven as endometrial carcinoma risk factor only for postmenopausal patients.

Although the histopathological assessment of the endometrial biopsy remains the gold standard, TVUS is considered to be the first step in any woman presenting with abnormal uterine bleeding [15]. A thin and regular endometrial line clearly visualized throughout the uterus is associated with a very low risk of endometrial carcinoma. Some authors believe that if endometrium is thinner than 5 mm measured by TVUS even with postmenopausal bleeding, the risk for carcinoma is low but not ruled out, especially in cases of persistent bleeding [16]. The value of TVUS in symptomatic premenopausal women and those using hormone substitution therapy is lower because the endometrial thickness regularly varies with changes of hormones during cycle. The data we obtained confirm previous findings which have shown that endometrial thickness above 5 mm in women with postmenopausal bleeding can be considered an accurate diagnostic parameter of endometrial malignancy [6]. However, there were no significant differences in endometrial thickness of pre- and postmenopausal women with endometrial carcinoma.

MRI is an important imaging modality in the preoperative assessment of endometrial carcinoma patients providing valuable data regarding lesion location and qualitative information for preoperative staging [17, 18]. MRI is able to accurately predict (sensitivity and specificity above 85%) cervical involvement in endometrial carcinoma patients and allows an adequate treatment decision [17, 19]. Some authors believe that reliability of MRI is better in the postmenopausal than in premenopausal women [18]. MRI findings in our population were mostly similar (echogenicity, homogeneity, endometrial thickness, level of cervical and myometrial invasion at the time of diagnosis, etc.) between pre- and postmenopausal women.

According to some available literature data, tumor volume influences the rate of endometrial carcinoma progression [20]. Based on our results, the size of tumor within the uterine cavity measured by MRI (filling the whole cavity) was confirmed to be a relevant parameter in premenopausal patients.

Some researchers have shown that positive peritoneal fluid cytology represents a marker for shorter time to recurrence of the disease and decreased survival rate of patients with endometrial carcinoma [21]. In the study population, only a few patients had ascites and enlargement of lymph nodes. Nevertheless, free fluid in the abdominal cavity seen by MRI was registered more often in the postmenopausal women.

Even though in the overall tested population the majority of carcinomas were diagnosed in early stages, numerous carcinomas in premenopausal patients were at FIGO stage II at the time of diagnosis. This might be due to the fact that irregular/abnormal bleeding in younger women is occasionally misdiagnosed and inappropriately treated.

---

**Table 4. Correlations and differences between investigated parameters regarding the menopausal status (pre- and postmenopausal) of women with endometrial carcinoma**

| Parameters               | Correlations | Differences |
|--------------------------|--------------|-------------|
|                          | Spearman ρ   | p           | KW χ² | p       |
| Body mass index          | 0.111        | 0.046       | 0.026 | 0.871   |
| Irregular/abnormal bleeding | 0.145       | 0.037       | 4.356 | 0.037   |
| Breast carcinoma         | -0.012       | 0.861       | 0.031 | 0.860   |
| Tamoxifen use            | 0.070        | 0.313       | 1.023 | 0.312   |
| Comorbidities            | 0.158        | 0.023       | 5.165 | 0.023   |
| Parity                   | -0.166       | 0.016       | 5.730 | 0.017   |
| Endometrium mm TVUS      | -0.026       | 0.704       | 0.145 | 0.703   |
| Homogeneity on TVUS      | -0.104       | 0.134       | 2.251 | 0.133   |
| Echogenicity on TVUS      | -0.040       | 0.563       | 0.338 | 0.561   |
| IU fluid on TVUS         | -0.106       | 0.126       | 2.348 | 0.125   |
| Myoma on TVUS            | -0.011       | 0.874       | 0.025 | 0.874   |
| Adnexal tumor on TVUS    | -0.019       | 0.787       | 0.073 | 0.786   |
| Pelvic metastases        | -0.095       | 0.170       | 1.887 | 0.170   |
| Ascites on TVUS          | 0.179        | 0.009       | 6.671 | 0.010   |
| Growth in uterine cavity on MRI | -0.155   | 0.025       | 4.978 | 0.026   |
| Cervix spreading on MRI  | -0.001       | 0.984       | 0.000 | 0.984   |
| Lymph nodes on MRI       | -0.049       | 0.483       | 0.496 | 0.481   |
| Myometrium on MRI        | -0.019       | 0.789       | 0.072 | 0.789   |
| Tumor grade              | 0.025        | 0.715       | 0.134 | 0.715   |
| FIGO stages (I, II, III) | -0.038       | 0.581       | 6.607 | 0.037   |
| HP DG                    | 0.079        | 0.258       | 1.287 | 0.257   |

HP DG – histopathological diagnosis; TVUS – transvaginal ultrasound; MRI – magnetic resonance imaging; IU – intrauterine; HRT – hormone replacement therapy; KW – Kruskal–Wallis
CONCLUSION

We confirmed that endometrial carcinoma is significantly more frequent in postmenopausal than in premenopausal women, while endometrioid adenocarcinoma is the most frequent histopathological diagnosis regardless of the menopausal status. There are few differences in endometrial carcinoma presentation/characteristics between pre- and postmenopausal patients. The presence of ascites was more frequent in postmenopausal women, while large exophytic endometrial carcinomas were predominant in younger patients. Endometrial thickness, uterine homogeneity, echogenicity, tumor infiltration and spreading at the time of diagnosis were similar between pre- and postmenopausal women with endometrial carcinomas. Although most women had BMI > 25, obesity presents an endometrial carcinoma risk factor for postmenopausal patients. Postmenopausal bleeding enables a diagnosis at earlier stages than irregular/abnormal bleeding in premenopausal patients. Ultrasound and MRI are appropriate diagnostic tools in patients with endometrial carcinoma, but their findings are not reliable for predicting tumor stage, grade, or exact histopathological diagnosis.

Conflict of interest: None declared.

REFERENCES

1. Fambrini M, Sorbi F, Sisti G, Cioni R, Turnini I, Taddei G, et al. Endometrial carcinoma in high-risk populations: is it time to consider a screening policy? Cytopathology. 2014; 25(2):71–7.
2. Kleebbkaow P, Maneetab S, Somboonporn W, Seejorn K, Thinkhamrop J, Komwilaisak R. Preoperative and Postoperative Agreement of Histopathological Findings in Cases of Endometrial Hyperplasia. Asian Pac J Cancer Prev. 2008; 9(1):89–91.
3. Sorosky JI. Endometrial cancer. Obstet Gynecol. 2008; 111(2 Pt 1):436–47.
4. Bonneau C, Perrin M, Koskas M, Genin AS, Rouzier R. Epidemiology and risk factors for cancer of the uterus. Rev Prat. 2014; 64(6):774–9.
5. Truskinovsky AM, Lifschitz-Mercer B, Czernobilsky B. Hyperplasia and carcinoma in secretory endometrium: a diagnostic challenge. Int J Gynecol Pathol. 2014; 33(2):107–13.
6. Dietz NK, Reth M, Thanner F, Dietl J. Diagnostic and preoperative staging of endometrial carcinoma with transvaginal sonography – a review. Zentralbl Gynakol. 2006; 128(5):246–54.
7. Colombo N, Preti E, Landoni F, Carinelli S, Colombo A, Marini C, et al. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013; 24 Suppl 6:v133–8.
8. McKenney JK, Longacre TA. Low-grade adenocarcinoma of the cervix: a diagnostic algorithm for distinguishing atypical endometrial hyperplasia and other benign (and malignant) mimics. Adv Anat Pathol. 2009; 16(1):1–22.
9. Robbins JR, Gayar OH, Zaki M, Mahan M, Bueters T, Elshaikh MA. Impact of Age-Adjusted Charlson Comorbidity score on outcomes for patients with early-stage endometrial cancer. Gynecol Oncol. 2013; 131(3):593–7.
10. AHIllii MM, Podratz KC, Dowdy SC, Bakkum-Gamez JN, Weaver AL, McGree ME, et al. Risk-scoring system for the individualized prediction of lymphatic dissemination in patients with endometrial carcinoma. Gynecol Oncol. 2013; 131(1):103–8.
11. La Vecchia C, Franceschi S, Decarli A, Gallus G, Tognoni G. Risk factors for endometrial cancer at different ages. J Natl Cancer Inst. 1984; 73(3):667–71.
12. Purdie DM, Green AC. Epidemiology of endometrial cancer. Best Pract Res Clin Obstet Gynaecol. 2001; 15(3):341–54.
13. Ward KK, Roncancio AM, Shah NR, Davis MA, Saenz CC, McHale MT, et al. The risk of uterine malignancy is linearly associated with body mass index in a cohort of US women. Am J Obstet Gynecol. 2013; 209(6):579.e1–5.
14. Hasumi K, Sugiyama Y, Sakamoto K, Akiyama F. Small endometrial carcinoma 10 mm or less in diameter: clinicopathologic and histogenetic study of 131 cases for early detection and treatment. Cancer Med. 2013; 2(6):872–80.
15. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet. 2005; 366(9484):491–505.
16. Chandavarkar U, Kuperman JW, Muderspach LI, Opper N, Felix JC, Roman L. Endometrial echo complex thickness in postmenopausal endometrial cancer. Gynecol Oncol. 2013; 131(1):109–12.
17. Nagar H, Dobbs S, McClelland HR, Price J, McCluggage WG, Grey A. The diagnostic accuracy of magnetic resonance imaging in detecting cervical involvement in endometrial cancer. Gynecol Oncol. 2006;103(2):431–4.
18. Wu WJ, Yu MS, Su HJ, Lin KS, Lu KL, Hwang KS. The accuracy of magnetic resonance imaging for preoperative deep myometrium assessment in endometrial cancer. Taiwan J Obstet Gynecol. 2013; 52(2):210–4.
19. Wan Q, Jiao Q, Li X, Zhou J, Zou Q, Deng Y. Value of (18)F-FDG PET/CT and MRI in diagnosing primary endometrial small cell carcinoma. Chin J Cancer Res. 2014; 26(5):627–31.
20. Yukiharu T, Hidemichi W, Kazuhira O, Hareyama H, Minobe S, T. Does positive peritoneal cytology not affect the prognosis for advanced endometrial carcinoma? Jpn J Cancer Res. 2012; 103(2):210–4.
Разлике у презентацији и карактеристикама карцинома ендометријума код жена у пременопаузи и постменопаузи

Саша Андрјашевић1, Јелена Дотлић1,2, Небојша Арсеновић3, Милан Терзић4,5,6
1Клинички центар Србије, Клиника за гинекологију и акушерство, Београд, Србија;
2Универзитет у Београду, Медицински факултет, Београд, Србија;
3Окружна болница, Одељење цепуларне патологије, Служба патологије Path Links, Линколн, Велика Британија;
4Универзитет „Назарбајев“, Медицински факултет, Одељење медицине, Астана, Казахстан;
5Универзитетски медицински центар, Национални истраживачки центар мајке и детета, Клиника за гинекологију и акушерство, Астана, Казахстан;
6Универзитет у Питсбургу, Медицински факултет, Клиника за гинекологију, акушерство и репродуктивне науке, Питсбург, Пенсилванија, САД

САЖЕТАК
Увод/Циљ У последње време карцином ендометријума се дијагностикује код све већег броја жена у пременопаузи. Циљ студије је био да се утврди да ли су рутински прикупљени клинички и imaging параметри, који могу да укажу на карактеристике тумора, различити код болесница са карциномом ендометријума у пременопаузи и постменопаузи, што би омогућило њихову правилну преоперативну процену.

Методе Студија је обухватала све болеснице (n = 209) описане због карцинома ендометријума током три године. Дијагноза је заснована на хистопатолошким налазима експлоративне киретаже. За све болеснице узета је детаљна анамнеза и оне су подељене према својом менопаузном статусу. На преоперативном ултразвучном прегледу одређен је “ехо образац” ендометријума. Регистровано је постојање миома, аднексалних маса, слободне течности у абдомену или у кавум утеруса. Магнетном резонанцом детектовано је присуство метастаза у малој карлици и ширење тумора на кавум утеруса, миометријум, грлић и лимфне чворове. Постоперативно су одређени хистопатолошки тип, стадијум и градус тумора.

Резултати Већина болесница су биле у постменопаузи и секундипаре. Значајно више болесница су биле гојазне, на рочито у постменопаузи (p = 0,001). Већина тумора су били ендометриоидни аденокарциноми без обзира на менопаузни статус. Нередово/абнормално крварење (p = 0,037), присуство асцитеса (p = 0,010), гојазност (p = 0,046) и нижи паритет (p = 0,016) били су повезани са постменопаузним статусом. Већи егзофитични карциноми ендометријума били су доминантан налаз код млађих болесница (p = 0,026). Карцином ендометријума је значајно чешће дијагностикован у FIGO стадијуму II код болесница у пременопаузи. Није било других значајних разлика (дебљина ендометријума, хомогеност и ехогеност материце, туморска инфилтрација и ширење, хистопатолошки тип и градус) између болесница са карциномом ендометријума у пременопаузи и постменопаузи.

Закључак Мале разлике су постојале између болесница са ендометријалним карциномом код жена у пременопаузи и постменопаузи, а најзначајније су биле гојазност, паритет, нередово/абнормално крварење и раст тумора ка материчкој шупљини.

Кључне речи: карцином ендометријума; менопаузни статус; ИТМ; ирегуларно крварење; преоперативна процена; ултразвучни преглед и магнетна резонанца

DOI: https://doi.org/10.2298/SARH181107055A

Andrijašević S. et al.